Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Therapy for Demoralization in Advanced Cancer
NCT07791901Phase 2Not yet recruiting
- Sponsor
- University of Calgary
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in existential distress and psychological distress (4 arms), sponsored by University of Calgary. Primary endpoints: Overall Trial Feasibility Based on Prespecified RED/YELLOW/GREEN Progression Criteria at 4 months and Incidence of Adverse Events at 4 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
existential distresspsychological distress
Beyond the preview
Go deeper on NCT07791901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791901.